Cerenome announced new preclinical findings that REYOBIQ, its investigational radiotherapeutic, works through a dual mechanism: causing lethal DNA damage to tumors and enhancing immune system activation. In ovarian cancer mouse models, REYOBIQ combined with anti-PD-1 checkpoint inhibitors improved tumor suppression and survival, turning immunologically resistant tumors into responsive ones. This suggests potential for REYOBIQ to enhance cancer immunotherapy, especially in hard-to-treat cancers like ovarian and brain tumors. Further studies are ongoing to explore its immunomodulatory effects across various cancers.
Cerenome's new dual mechanism of action for its investigational drug REYOBIQ provides context for the health sector. For readers following health stocks, here is Pluang's market snapshot as of Oct 21, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 71 rose and 67 fell. Notable movers include TNGX at USD 26.20 (+3.76%), BAX at USD 25.30 (+3.22%) with balanced buy/sell orders, and NUVB at USD 4.91 (+2.94%).
The BBB National Programs’ National Advertising Division reviewed Royal Caribbean Group's advertising related to gratuities and found the company's recent modifications to be supported. Royal Caribbean clarified in its booking process that gratuities...
Deutsche Bank increased its price target for Kroger to $70 from $68, reflecting a potential 10.7% upside. Kroger announced strategic growth initiatives including a $5 billion customer-value investment and plans to open 110 new stores by 2029. The com...
Crown Castle is set to report its Q3 2026 earnings with Wall Street expecting a 5.9% revenue decline to about $1.01 billion, mainly due to drops in site rental and services revenue. However, some forecasts predict a 7.1% rise in earnings per share to...
PypeServer has released Cloud+ version 3.0, enabling HVAC contractors to manage both ductwork and piping fabrication on a single platform. This update allows seamless tracking from design through installation, integrating with existing design softwar...
Kevel secured $52 million in its largest funding round to date, boosting its AI-powered infrastructure for commerce media networks. The capital will accelerate product innovation, transparent AI decisioning, and global expansion, helping retailers an...
